Posts Tagged ‘Op-ed’
Counterfeit HIV drug underscores risks of a weaker drug supply chain, advocate warns.
ADAP Advocacy Association CEO Brandon M. Macsata wrote this editorial, which appeared on the AIDS Drug Assistance Program’s website on April 1, 2021.
The Association first warned constituents that counterfeit Symtuza had been distributed to three U.S. pharmacies in December 2020, when Janssen issued an alert.
[...]Canada’s Actions a Death-Knell for Drug Importation in Florida
This editorial by the Sun Sentinel Editorial Board was published in The Sun Sentinel on December 9, 2020. The Editorial Board consists of Editorial Page Editor Rosemary O’Hara, Dan Sweeney, Steve Bousquet and Editor-in-Chief Julie Anderson. There Go Those Cheaper Drugs. Remember Florida’s plan to save money by importing prescription drugs in bulk from Canada?…
[...]Canadian writer applauds country’s effort to protect its drug supply
This editorial by Joyce Nelson appeared in Counter Punch on December 4, 2020. Nelson is a researcher and writer whose work appears in a wide range of magazines, newspapers and websites.
[...]Organizer explains why drug importation is dangerous and “doomed to fail”
This editorial, written by Earl D. Fowlkes Jr., appeared in the Washington Blade on December 4, 2020. Fowlkes is the president and CEO of the Center for Black Equity.
[...]Importation was “a waste of valuable federal and state tax dollars,” says fiscally-focused advocacy group
In this editorial, which was posted on December 2, 2020, Citizens Against Government Waste decries the expense and futility drug importation.
[...]There is no Way to Regulate the Quality of Drugs Imported by American Patients
This editorial by Brandon Macsata was published in The International Business Times on November 1, 2020. Macsata has been living with HIV since 2002, and serves as the CEO of the ADAP Advocacy Association, an organization that promotes the AIDS Drug Assistance Program and works to improve access to care.
[...]“Reducing costs requires more than all of this non–value-added activity,” Expert Says
In this October 23, 2020 editorial, which was published in the The American Journal of Managed Care, Michael Abrams explains why drug importation will not save patients money. Abrams is the co-founder and managing partner of Numerof & Associates.
[...]“…barriers will delay or prevent drug importation,” say regulatory experts
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
[...]US Attorney for Arizona Calls Illicit Fentanyl “The Most Dangerous Drug We Have Confronted as a Nation”
In the first seven months of 2020, the Arizona Department of Health Services reported over 2,700 newly suspected opioid overdose deaths in Arizona. What makes this figure more startling is that there were just over 3,800 suspected opioid deaths in the preceding 30 months. The problem is escalating, and rapidly.
[...]Newspaper Editorial Board Says Canadian Drug Importation Will Have Limited Impact
The editorial board of the Florida Times-Union published an op-ed that states that Canadian drug importation will have a limited impact, and is a sign of a broken system, not a solution to one…
[...]